X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (55) 55
index medicus (36) 36
male (27) 27
oncology (27) 27
middle aged (20) 20
female (18) 18
aged (16) 16
adult (15) 15
cancer (15) 15
tumors (11) 11
melanoma - immunology (10) 10
care and treatment (9) 9
hematology (9) 9
immunotherapy (9) 9
melanoma (9) 9
animals (8) 8
antigens, neoplasm - immunology (8) 8
breast cancer (8) 8
chemotherapy (8) 8
immunology (8) 8
renal cell carcinoma (8) 8
urology (8) 8
urology & nephrology (8) 8
dendritic cells (7) 7
metastasis (7) 7
treatment outcome (7) 7
aged, 80 and over (6) 6
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
carcinoma, renal cell (6) 6
cd8-positive t-lymphocytes - immunology (6) 6
clinical trials (6) 6
hematology, oncology and palliative medicine (6) 6
medicine, research & experimental (6) 6
mice (6) 6
neoplasm metastasis (6) 6
peptide (6) 6
research (6) 6
testicular neoplasms - drug therapy (6) 6
thromboplastin - metabolism (6) 6
tissue factor (6) 6
tumor cells, cultured (6) 6
vaccination (6) 6
antineoplastic agents - adverse effects (5) 5
cell line, tumor (5) 5
flow cytometry (5) 5
foods or foodstuffs (5) 5
foods, foodstuffs, or non-alcoholic beverages, not covered bysubclasses a23b - a23j (5) 5
human necessities (5) 5
hygiene (5) 5
indexing scheme relating to foods, foodstuffs or non-alcoholicbeverages (5) 5
kidney neoplasms - pathology (5) 5
medical or veterinary science (5) 5
melanoma - therapy (5) 5
peripheral vascular disease (5) 5
preparations for medical, dental, or toilet purposes (5) 5
preservation of foods or foodstuffs, in general (5) 5
specific therapeutic activity of chemical compounds ormedicinal preparations (5) 5
sunitinib (5) 5
survival (5) 5
t-lymphocytes, cytotoxic - immunology (5) 5
their preparation or treatment, e.g. cooking, modification ofnutritive qualities, physical treatment (5) 5
their treatment, not covered by other classes (5) 5
time factors (5) 5
angiogenesis (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
biotechnology & applied microbiology (4) 4
breast neoplasms - pathology (4) 4
cancer patients (4) 4
carcinoma, renal cell - drug therapy (4) 4
cohort studies (4) 4
drug therapy (4) 4
europe (4) 4
further section · weitere sektionen (4) 4
genetics & heredity (4) 4
health aspects (4) 4
in-vivo (4) 4
kidney cancer (4) 4
lymphocytes (4) 4
medicine (4) 4
melanoma - metabolism (4) 4
microparticles (4) 4
neoplasm staging (4) 4
oncology, experimental (4) 4
peripheral-blood (4) 4
prostate cancer (4) 4
risk (4) 4
risk factors (4) 4
skin neoplasms - immunology (4) 4
t cells (4) 4
testicular cancer (4) 4
testicular neoplasms (4) 4
therapy (4) 4
thrombosis (4) 4
toxicity (4) 4
antigen (3) 3
antigens, neoplasm - analysis (3) 3
antigens, neoplasm - metabolism (3) 3
antigens, surface (3) 3
cancer-patients (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Therapeutic Advances in Urology, ISSN 1756-2872, 03/2018, Volume 10, Issue 3, pp. 109 - 123
Cabozantinib is an oral multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell... 
targeted therapy | renal cell cancer | AXL | vascular endothelial growth factor receptor | tyrosine kinase inhibitor | MET | cabozantinib | SURVIVAL | EVEROLIMUS | PAZOPANIB | BLIND PHASE-III | OPEN-LABEL | SORAFENIB | MET EXPRESSION | INTERFERON-ALPHA | C-MET | SUNITINIB | UROLOGY & NEPHROLOGY | Vascular endothelial growth factor | Medical prognosis | Kidney cancer
Journal Article
Journal Article
Journal Article
Journal Article
by Witjes, J. Alfred and Babjuk, Marek and Bellmunt, Joaquim and Bruins, H. Maxim and De Reijke, Theo M and De Santis, Maria and Gillessen, Silke and James, Nicholas and Maclennan, Steven and Palou, Juan and Powles, Tom and Ribal, Maria J and Shariat, Shahrokh F and Der Kwast, Theo Van and Xylinas, Evanguelos and Agarwal, Neeraj and Arends, Tom and Bamias, Aristotle and Birtle, Alison and Black, Peter C and Bochner, Bernard H and Bolla, Michel and Boormans, Joost L and Bossi, Alberto and Briganti, Alberto and Brummelhuis, Iris and Burger, Max and Castellano, Daniel and Cathomas, Richard and Chiti, Arturo and Choudhury, Ananya and Compérat, Eva and Crabb, Simon and Culine, Stephane and De Bari, Berardino and De Blok, Willem and J.L. De Visschere, Pieter and Decaestecker, Karel and Dimitropoulos, Konstantinos and Dominguez-Escrig, Jose L and Fanti, Stefano and Fonteyne, Valerie and Frydenberg, Mark and Futterer, Jurgen J and Gakis, Georgios and Geavlete, Bogdan and Gontero, Paolo and Grubmüller, Bernhard and Hafeez, Shaista and Hansel, Donna E and Hartmann, Arndt and Hayne, Dickon and Henry, Ann M and Hernandez, Virginia and Herr, Harry and Herrmann, Ken and Hoskin, Peter and Huguet, Jorge and Jereczek-Fossa, Barbara A and Jones, Rob and Kamat, Ashish M and Khoo, Vincent and Kiltie, Anne E and Krege, Susanne and Ladoire, Sylvain and Lara, Pedro C and Leliveld, Annemarie and Linares-Espinós, Estefania and Løgager, Vibeke and Lorch, Anja and Loriot, Yohann and Meijer, Richard and Mir, M. Carmen and Moschini, Marco and Mostafid, Hugh and Müller, Arndt-Christian and Müller, Christoph R and N'Dow, James and Necchi, Andrea and Neuzillet, Yann and Oddens, Jorg R and Oldenburg, Jan and Osanto, Susanne and J.G. Oyen, Wim and Pacheco-Figueiredo, Luís and Pappot, Helle and Patel, Manish I and Pieters, Bradley R and Plass, Karin and Remzi, Mesut and Retz, Margitta and Richenberg, Jonathan and Rink, Michael and Roghmann, Florian and Rosenberg, Jonathan E and Rouprêt, Morgan and Rouvière, Olivier and Salembier, Carl and Salminen, Antti and Sargos, Paul and ...
European Urology, ISSN 0302-2838, 11/2019
Journal Article
Journal Article
Future Oncology, ISSN 1479-6694, 09/2013, Volume 9, Issue 9, pp. 1271 - 1281
Tasquinimod, an oral quinolone-3-carboxamide with anti-tumor activity in preclinical models of prostate cancer, has been tested in patients with minimally... 
prostate cancer | castration-resistant prostate cancer | tasquinimod | antiangiogenic agent | quinoline-3-carboxamide | THROMBOSPONDIN-1 | ANTI-ANGIOGENIC AGENT | OPEN-LABEL | TUMOR ANGIOGENESIS | HAMSTER | ABR-215050 | INHIBITION | ONCOLOGY | INCREASED SURVIVAL | ACCUMULATION | ABIRATERONE | Index Medicus
Journal Article
Haematologica, ISSN 0390-6078, 01/2013, Volume 98, Issue 1, pp. 153 - 158
Tissue factor activation (decryption) has been proposed to be dependent on the cysteine 186-cysteine 209 allosteric disulfide in the tissue factor... 
Disulfides - metabolism | Cell Line | Cricetinae | Allosteric Regulation | Humans | Disulfides - blood | Cysteine - genetics | Animals | Thromboplastin - genetics | Cysteine - metabolism | Mice | Thromboplastin - metabolism | Cysteine - blood
Journal Article
Therapeutic Advances in Urology, ISSN 1756-2872, 2/2012, Volume 4, Issue 1, pp. 3 - 12
This review examines the development and efficacy of novel treatment options for advanced prostate cancer and discusses novel therapies that are on the... 
MDV3100 | sipuleucel-T | abiraterone | zoledronic acid | cabazitaxel | castration-resistant prostate cancer | denosumab | Reviews
Journal Article
Journal Article